deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT01380938

Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) (WRITE)

RCT Comparing Different Ribavirin Dosages and Durations of Treatment in Combination With Peginterferon in HCV Genotypes 2 and 3 (WRITE)

Sponsor: Arcispedale S. Anna, Ferrara

Conditions Chronic Hepatitis
Interventions Peginterferon alpha-2a + Ribavirin
Updated 9 times since 2017 Last updated: Mar 9, 2022 Started: Dec 1, 2018 Primary completion: Nov 30, 2019 Completion: Nov 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01380938, this PHASE3 trial focuses on Chronic Hepatitis and remains completed. Sponsored by Arcispedale S. Anna, Ferrara, it has been updated 9 times since 2018, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshotUnknown Status~Apr 2019 – ~Jan 2021 · 21 months · monthly snapshotUnknown Status~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotUnknown Status~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshotCompleted~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE3

  5. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Unknown Status → Completed

▶ Show 4 earlier versions

  1. Jan 2021 — Apr 2022 [monthly]

    Unknown Status PHASE3

  2. Apr 2019 — Jan 2021 [monthly]

    Unknown Status PHASE3

  3. Jun 2018 — Apr 2019 [monthly]

    Unknown Status PHASE3

  4. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arcispedale S. Anna, Ferrara
  • Azienda Ospedaliera V. Cervello
  • Azienda Ospedaliera, Lucca
  • Azienda Ospedaliera, Siracusa
  • Azienda Ospedaliero Universitaria di Sassari
  • Azienda Ospedaliero-Universitaria Careggi
  • Azienda Ospedaliero-Universitaria, Catania
  • Campus Bio-Medico University
  • Cardarelli Hospital
  • Casa Sollievo della Sofferenza IRCCS
  • Casa di Cura Mater Dei
  • Fondazione IRCCS Policlinico San Matteo di Pavia
  • IRCCS De Bellis, Castellana
  • IRCCS L. Spallanzani
  • Ospedale Civile Spirito Santo
  • Ospedale Civile Vittorio Emanuele II, Bisceglie
  • Ospedale Francesco Ferrari
  • Ospedale Monsignor R. Dimiccoli, Barletta
  • Ospedale SS. Annunziata, Taranto
  • Ospedale San Giuseppe Moscati, Avellino
  • Ospedale Sandro Pertini, Roma
  • Ospedale Santa Caterina Novella, Galatina
  • Ospedale Valduce, Como
  • Ospedale di Canosa di Puglia
  • Ospedale di Mottola
  • Ospedale di Venosa
  • Ospedali Riuniti di Foggia
  • San Camillo Hospital, Rome
  • USL Napoli 1
  • University of Bari
  • University of Florence
  • University of Palermo
Data source: Casa Sollievo della Sofferenza IRCCS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Avellino, Italy , Bari, Italy , Barletta, Italy , Bisceglie, Italy , Canosa di Puglia, Italy , Casarano, Italy , Castellana Grotte, Italy , Catania, Italy , Como, Italy , Ferrara, Italy and 15 more locations